Helix and Mawi join hands to support genomic sequencing

Introduction

Helix is a famous viral surveillance and population genomics company, also known for its smart collaborations with payers, life sciences industries and the health sector for providing genomic data to the research and clinical care unit. The company is remembered for its SARS-CoV-2 sequencing offering for the CDC during the deadly pandemic.

Mawi DNA Technologies is known for convincing and impressive non-invasive biosample collection technology. The company’s star iSWAB™ platform and its products aims on temperature control, effective, efficient and quality RNA/DNA collection. The collection is formed from different sources like microbiomes, blood and buccal cells.

Announcement

Mawi and Helix announced their partnership for Helix’s improvement and boost to the extending potential value to attract new patient population without compromising the multimodal thought and flexibility to the genomics cohort. Helix sees Mawi as a perfect partner for this improvisation, as Mawi has established and proven buccal collection technology.

The technology picks the swabbing cells directly from the cheeks of the enrolled population for the analysis. The idea is easy to execute without any pain or time-consuming additional activities. It is engineered to enhance collection efficiency and cut the chances of failures, expensive operational cost and mitigate the resampling.

Helix found a solution to its struggles

Helix considers numerous DNA collection methods involving saliva and blood, as no single great idea is sufficient in a use case or in a huge individual cohort. Helix noticed that saliva-based collection can bring out challenges for older adults, individuals with any chronic conditions and infants, which also hammers saliva production.

Now Helix will also experience the use of buccal swabs, but this time with Tech Touch by Mawi. Buccal swabs are alternatives to stay in line with continuous sample collection. Helix's consideration and approaches have always been clear, which encouraged the company to choose this partnership wisely to add the best to the sample collection process.

Alongside, Helix’s sequencing programs will get a flexible collection push with more reliable data creation suitable for several types of groups. This will attract more businesses and patient engagements, trusting this technology. This will help Helix to perform excellently in life sciences and health systems with its extensive contribution by providing various advocated routes to continue capturing and building the quality genomic data.

CEO of Helix, PhD, M.D., James Lu, said, “This new buccal swab collection with the existing saliva and blood options we are helping our partners to effortlessly design programs suitable to particular environments and populations.”